Please find enlcosed UFR Q1 FY 27.
RESULTS
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 29 Jul 2026, 08:51 PM IST · BSE ID: 6efdbf59-8bf0-4b73-91e6-ccb643a1e5f1
View Original BSE Filing (PDF)
💡
In Simple Terms
Piramal Pharma announced its first quarter financial results for fiscal year 2027, showing increased revenue but a consolidated loss.
🤖 AI Summary
- Piramal Pharma Board approved Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 (Q1 FY27).
- Standalone revenue from operations for Q1 FY27 was Rs. 1,124.95 Crores, up 16.0% from Q1 FY26.
- Standalone Net Profit after tax for Q1 FY27 stood at Rs. 113.48 Crores, showing a 0.3% increase year-on-year.
- Consolidated revenue from operations for Q1 FY27 reached Rs. 2,269.92 Crores, a 17.4% increase from Q1 FY26.
- Consolidated Net Loss after tax for Q1 FY27 was Rs. (69.39) Crores, compared to a net loss of Rs. (81.70) Crores in Q1 FY26.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from operations (Q1 FY27)
1,124.95 Rs. in Crores
16.0%
Standalone Net Profit after tax (Q1 FY27)
113.48 Rs. in Crores
0.3%
Consolidated Revenue from operations (Q1 FY27)
2,269.92 Rs. in Crores
17.4%
Consolidated Net Profit/ (Loss) after tax (Q1 FY27)
(69.39) Rs. in Crores
Standalone Basic EPS (Q1 FY27)
0.85 Rs.
0.0%
🏢 How This Affects the Company
Standalone revenue from operations increased by 16.0% year-on-year to Rs. 1,124.95 Crores for Q1 FY27, indicating growth in its core business activities.
The company reported a standalone Net Profit after tax of Rs. 113.48 Crores, while consolidated results showed a net loss of Rs. (69.39) Crores, impacting overall profitability.
Total expenses for standalone operations increased to Rs. 1,090.10 Crores in Q1 FY27 from Rs. 1,008.22 Crores in Q1 FY26, reflecting higher operational costs.
The consolidated net loss of Rs. (69.39) Crores for Q1 FY27, despite increased revenue, highlights potential challenges in managing overall group profitability.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, with standalone net profit at Rs. 113.48 Crores and consolidated net loss at Rs. (69.39) Crores impacting per-share earnings.
🔍
Management Signal
The Board's approval and disclosure of both standalone and consolidated results indicates adherence to regulatory requirements and transparency regarding group financial status.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — monitor consolidated profitability trends.
Updates on strategies to improve consolidated net profit.
Any further disclosures regarding operational efficiency initiatives.
MEDIUM RISK
Sustained consolidated net losses despite revenue growth suggest underlying profitability challenges.
💡 Investor Takeaway
Piramal Pharma's standalone Q1 FY27 revenue from operations grew 16.0% YoY to Rs. 1,124.95 Crores, with Net Profit after tax at Rs. 113.48 Crores. However, consolidated results show a Net Loss after tax of Rs. (69.39) Crores for the same period.
⚖️ Strengths & Concerns
✅ Positives
- Standalone Revenue from operations for Q1 FY27 increased to Rs. 1,124.95 Crores, a 16.0% rise compared to Rs. 969.88 Crores in Q1 FY26.
- Consolidated Revenue from operations for Q1 FY27 grew by 17.4% year-on-year, reaching Rs. 2,269.92 Crores from Rs. 1,933.71 Crores in Q1 FY26.
⚠️ Concerns
- Consolidated Net Loss after tax for Q1 FY27 was Rs. (69.39) Crores, following a loss of Rs. (8.82) Crores in the previous quarter and Rs. (81.70) Crores in Q1 FY26.
- Standalone total expenses increased by 8.1% year-on-year to Rs. 1,090.10 Crores in Q1 FY27, indicating higher cost base.
📅 Company Track Record
Previous filing on 2026-07-29 indicated Piramal Pharma's Q1 FY27 standalone revenue was up 16.0% to Rs. 1,124.95 Crores. This filing provides the full unaudited standalone and consolidated results for the quarter.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Piramal Pharma's standalone revenue from operations in Q1 FY27?
Piramal Pharma's standalone revenue from operations for the quarter ended June 30, 2026, was Rs. 1,124.95 Crores.
What was Piramal Pharma's standalone net profit after tax in Q1 FY27?
The standalone Net Profit after tax for Piramal Pharma in Q1 FY27 was Rs. 113.48 Crores.
What was Piramal Pharma's consolidated revenue from operations in Q1 FY27?
Piramal Pharma's consolidated revenue from operations for the quarter ended June 30, 2026, was Rs. 2,269.92 Crores.
What was Piramal Pharma's consolidated net profit or loss after tax in Q1 FY27?
Piramal Pharma reported a consolidated Net Loss after tax of Rs. (69.39) Crores for the quarter ended June 30, 2026.
How did Piramal Pharma's standalone basic EPS perform in Q1 FY27?
Piramal Pharma's standalone Basic EPS for Q1 FY27 was Rs. 0.85, consistent with Rs. 0.85 in Q1 FY26.
Questions based on this BSE filing only. For information purposes.